Randomized controlled study of the influence of two low @entity172 dose oral contraceptives containing @entity2081 or XXXX on @entity1735 metabolism.

@entity1 @entity172 @entity2081 @entity2082 @entity2690 @entity1735 @entity5252 @entity7281 @entity413
This study compared the impact on @entity1735 metabolism of two combinedoral contraceptives (COCs). This open-label, single-center trial enrolled @entity1 for a total of 15 cycles. Thirty-six @entity1 were randomized to receive either 20 microg @entity2082 (EE) and 75 microg gestodene (GSD) or 20 microg @entity2082 and 150 microg @entity7281 ( @entity5252 ) daily for 21 days out of 28. A @entity413 tolerance test was performed at baseline and cycles 6 and 13. The area under the curve (AUC) for @entity413 increased in both study groups. The change was statistically significant (p = 0.036) for the 20 EE/75 GSD group at cycle 6 versus baseline. Fasting blood @entity413 at cycle 13 was significantly (p < 0.01) higher for both treatment groups compared to baseline. No changes were found for fasting insulin and fasting @entity2690 levels or for the AUCs of insulin or @entity2690 . Both regimens were well tolerated. @entity2081 and @entity7281 in combination with 20-microg @entity2082 induce similar changes in @entity1735 metabolism which are smaller than those described earlier for COCs containing higher @entity172 doses or more androgenic progestins such as levonorgestrel.
